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Abstract
Introduction: Acute deterioration of cirrhosis is associated with high mortality rates particularly in the patients
who develop organ failure (OF), a condition that is referred to as acute-on-chronic liver failure (ACLF), which is
currently not completely defined. This study aimed to determine the role of predisposing factors, the nature of the
precipitating illness and inflammatory response in the progression to OF according to the PIRO (predisposition,
injury, response, organ failure) concept to define the risk of in-hospital mortality.
Methods: A total of 477 patients admitted with acute deterioration of cirrhosis following a defined precipitant
over a 5.5-year period were prospectively studied. Baseline clinical, demographic and biochemical data were
recorded for all patients and extended serial data from the group that progressed to OF were analysed to define
the role of PIRO in determining in-hospital mortality.
Results: One hundred and fifty-nine (33%) patients developed OF, of whom 93 patients died (58%) compared with
25/318 (8%) deaths in the non-OF group (P < 0.0001). Progression to OF was associated with more severe
underlying liver disease and inflammation. In the OF group, previous hospitalisation (P of PIRO); severity of
inflammation and lack of its resolution (R of PIRO); and severity of organ failure (O of PIRO) were associated with
significantly greater risk of death. In the patients who recovered from OF, mortality at three years was almost
universal.
Conclusions: The results of this prospective study shows that the occurrence of OF alters the natural history of
cirrhosis. A classification based on the PIRO concept may allow categorization of patients into distinct
pathophysiologic and prognostic groups and allow a multidimensional definition of ACLF.
Introduction
WHO projections estimate that liver cirrhosis will be
the ninth most common cause of death in the western
world by 2015. The cost of management of patients who
require hospital admission with acute deterioration in
the US approximates $13 billion [1]. In a significant pro-
portion of such patients, death is related to multiple organ
failure, which, when manifest, carries a high mortality rate.
Currently, these patients do not have priority for listing
for liver transplantation and often such patients are con-
sidered to be too ill for transplantation [2]. Conceptually,
this multiorgan failure can occur either as a slow gradually
progressive decompensation culminating in multiple
organ failure or it can occur as a result of a precipitating
illness, which is often of non-hepatic origin [3] on the
background of cirrhosis in a previously stable cirrhotic
patient, who may or may not have a history of decompen-
sation. While both entities can lead to various features of
multiorgan failure the underlying mechanisms of decom-
pensation are probably quite different and, therefore,
hypothetically the clinical outcome is likely to be different.
This latter condition has been referred to in the literature
as having acute-on-chronic liver failure (ACLF) [4].
In order to clinically describe the group of patients
referred to as ACLF, we adopted the definition that these
patients would have ‘acute deterioration in liver function
over a short period (up to four weeks)’ ‘associated with a
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precipitating event’ ‘in patients with previously well-com-
pensated liver disease’ ‘characterised by organ failure’ [5].
We also hypothesised that from the clinical standpoint the
most important difference between the two entities is the
potentially reversible nature of ACLF if precipitants could
be controlled.
Several studies have addressed the outcome of patients
with liver cirrhosis and organ failure. The requirement for
ICU admission in patients with cirrhosis was associated
with high mortality rates ranging from 40 to 90%. Wehler
et al. [6] assessed the impact of organ failure and showed
that the presence of organ failure with the Sepsis Organ
Failure Assessment (SOFA) score of 9 or greater was asso-
ciated with a short-term mortality of about 90%. However,
this study did not specifically address the question if there
is a difference between patients with acute deterioration
compared to those with end-stage liver disease. Identifica-
tion of patients at risk of progressing to multiorgan failure
would help substantially in prioritising patients for early
intensive therapy, transfer to specialist tertiary referral
units, liver support and listing for transplantation.
We hypothesised that a concept similar to that used in
determining outcomes of sepsis [7] may be useful in defin-
ing outcomes in patients who develop organ failure, the
PIRO concept; Predisposition (P); Injury (I) by the nature
of the insult leading to decompensation; Response (R) to
this insult and the development of organ failure (O) are
the four most important factors determining outcome.
The aim of this study was to define the natural history of
patients with acute deterioration of cirrhosis without exist-
ing organ failure other than liver cirrhosis that were
admitted to the hospital and investigate the factors leading
to occurrence of organ failure in the hospital and death.
In this study, a group of patients with liver cirrhosis
that were admitted to a single unit over a 5.5-year period
and managed according to pre-defined protocol were
recruited. The main questions the prospective study was
set up to answer were whether the outcome of patients
with acute decompensation of cirrhosis due to a defined
precipitant who progress to single organ failure in com-
parison to those who do not develop organ failure was
different and determine the factors associated with mor-
tality of patients with organ failure. We also determined
whether a previous episode of decompensation influences
outcome and whether the inflammatory response to the
precipitating illness was associated with poor outcome.
Materials and methods
Consecutive patients with liver cirrhosis admitted to the
University College London Hospitals (UCLH) with decom-
pensated liver cirrhosis between July 2000 and January
2006 were evaluated for entry into the study. This pro-
spective single-centre study was performed on a group of
patients that were in a pre-screen log for inclusion into a
randomised study of liver support device (treatment of dis-
turbed inter-organ metabolism in decompensated cirrhosis
using molecular adsorbent recirculating system (MARS)).
This study was approved by the UCLH Ethics Committee
and conducted according to the Declaration of Helsinki.
As the patients were a part of a pre-screening log, no addi-
tional consent was required.
Recruitment and study enrolment
All patients of any age with an acute clinical deterioration
of presumed cirrhosis (elevated bilirubin > 85 μmol/L,
or/and increasing ascites or/and hepatic encephalopathy
< grade 2) related to a clear precipitating event (infection,
bleeding, alcoholic hepatitis, exposure to hepatotoxins)
were included and data were collected retrospectively
and prospectively. The diagnosis of cirrhosis was con-
firmed either by liver biopsy or by clinical signs (signs of
portal hypertension and imaging concordant with cirrho-
sis). The patients were included if they failed to show
signs of improvement in their presenting complaints or
biochemistry, 48 hours after admission and following
correction of precipitating illnesses.
Exclusion criteria: admission for reasons other than
decompensation of cirrhosis (other co-morbid diseases,
especially established cardiovascular or renal disease); pre-
sence of organ failure (as defined later), malignancy (extra-
hepatic or a hepatocellular carcinoma); patients who have
undergone major surgery (for example liver resection) or
have unsolved surgical problems; pregnancy.
Study design and management
All patients were followed up until the end of the study,
death or liver transplantation. Survival data for the sur-
viving patients were available for one year after the end
of the study (end 2006). Patients were managed accord-
ing to a pre-defined standard of care and all patients that
were included had the potential to be supported with full
intensive care if required. Briefly, the standard of care for
the patients included the following:
1. Nutritional support: enteral feeding with a calorie
intake > 30 Kcal/Kg/day with additional vitamin supple-
mentation especially in alcoholic patients.
2. Evidence of suspected or culture-positive infection:
intravenous antibiotics covering gram-positive and
-negative organisms in accordance with local institution
microbiology policies.
3. Re-accumulation of ascites: sodium chloride restric-
tion (≤ 100 mmol/day) and therapeutic paracentesis
with albumin replacement (8 g/litre of ascites removed).
4. New onset renal impairment: fluid challenge with col-
loid and crystalloid, and if deemed to have developed
hepatorenal syndrome, managed with terlipressin 0.5 to
2 mg intravenously, up to six times daily concurrent with
infusion of 60 g salt-poor albumin.
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5. Progressive organ failure (defined below): full inten-
sive care support including haemofiltration or/and venti-
lation, as indicated.
Definitions
1. Definition of organ failure was based on modification
of the SOFA score:
a. Circulation: need for inotropes to maintain mean
arterial pressure greater than 65 mmHg (modified
SOFA: 3 or 4); the use of terlipressin for hepatorenal
syndrome was not considered as inotropic support but a
specific treatment hepatorenal syndrome.
b. Renal and acid-base disturbances: requirement for
haemofiltration to correct acidosis and/or oligo-anuria
with serum creatinine > 221 umol/L following correction
of any intravascular volume deficit and with no evidence
of pre-existing renal failure (modified SOFA: 2 or more).
c. Inadequate oxygenation: PO2/FIO2 > 200 of SpO2/
FiO2 < 214 or requirement for mechanical ventilation to
maintain an arterial partial pressure of oxygen > 10 kPA
(modified SOFA: 3 or 4).
d. Severe encephalopathy: grade 3 and 4 and/or need
for mechanical ventilation for airway compromise (mod-
ified SOFA: 4).
e. Severe progressive hyperbilirubinaemia: a progres-
sive increase in bilirubin to > 340 umol/dl (modified
SOFA: 4).
f. Severe coagulopathy: INR > 2.5 or platelet count ≤
20,000 (modified SOFA: 4).
2. Systemic Inflammatory Response Syndrome (SIRS)
was defined by the presence of two or more of the follow-
ing: temperature > 38°C or < 36°C; heart rate > 90 beats/
min; respiratory rate > 20 per min or PaCO2 < 32 mmHg;
white blood cells > 12,000 cells/mm3 or < 4000 cells/mm3.
3. Infection-positive cultures of blood, ascites, urine, spu-
tum or wounds and/or clinical findings suggestive for infec-
tions (chest X-ray). A new (nosocomial) infection was
defined as an infection that occurred more than 48 hours
after admission or 48 hours after clearance of an existing
infection. The diagnosis of infection in this study was based
on standard routine clinical procedures. It is not possible to
exclude the rate of diagnosis of bacterial infection, which
would have been higher if more rigorous testing was used.
In order to ensure reproducibility of diagnosis, the use of
antibiotics in this group of patients for either confirmed or
presumed diagnosis of bacterial infection is always done in
close discussion with a designated microbiologist.
Data collection
Baseline data and mortality were recorded for all patients
and an extended dataset including serial data at days 0
(onset of organ failure), 3 and 7 regarding clinical and
demographic variables were determined in the organ fail-
ure group (Table S2 in Additional file 1). Child-Pugh
score and Model for End-Stage Liver Disease (MELD)
score evaluated severity of liver disease at days 0, 3 and 7.
Acute Physiology, Age and Chronic Health Evaluation
(APACHE) II score was used for determination of illness
severity and the SOFA score for grading of organ dysfunc-
tion at days 0, 3, and 7. The presence or absence of SIRS
was recorded at days 0, 3 and 7 and the number of failing
organs during the first week on an Intensive Care Unit
(ICU) was counted according to the above definition.
SOFA score was calculated as published with a few
modifications.
APACHE II and SOFA scores were calculated after the
onset of organ failure. Some patients were not on an ICU
at the onset of organ failure. Since we do not have data on
the reason why patients were not admitted to ICU, we cal-
culated these scores for all patients with organ failure
[6,8-12].
Statistical methods
Comparison of demographic and clinical parameters
between groups was performed using independent variable
t test or Mann-Whitney U tests for continuous variables
and chi-square tests for categorical variables. More than
two groups were compared using two-way ANOVA.
Survival curves of two groups were compared graphically
using the method of Kaplan-Meier, counting death as
event. The equality of the dichotomised groups was tested
via log-rank test. The discrimination ability of single para-
meters or scores to predict outcome of patients was evalu-
ated by calculating the area under the receiver operating
characteristics curve (AUROC). The Younden Index was
used to select the best cutoff point, at which sensitivity,
specificity, positive predictive value and negative predictive
value were calculated. To identify factors that were inde-
pendently associated with outcome (30-day mortality, cen-
sored at time of transplantation), univariate and
multivariable logistic regression analysis were performed.
Risk factors with a significance of P < 0.10 in the univari-
ate analysis were entered manually into the multivariable
model using stepwise selection. The scores (SOFA,
APACHE II, Child and MELD) were not incorporated into
the multivariable analysis. The statistical significance level
was set as P < 0.05. Continuous variables were sum-
marised as mean ± SEM, and categorical variables were
summarised as proportions. Results from logistic regres-
sion were given as odds ratio (OR) and 95% confidence
intervals (CI). All analyses were carried out using SPSS




In total 497 inpatients admitted for acute deterioration
of cirrhosis were recruited into the study (Table 1).
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Twenty patients were excluded from the final analysis
because of lack of data or not fulfilling study criteria. The
study group, therefore, consisted of 477 patients. Three
hundred and eighteen patients did not develop organ fail-
ure (non-organ failure group from here). (Figure 1)
Thirty-day mortality in the non-organ failure group was
8% (Figure 2a) and the one-year mortality was 42%. A
total of 159 patients developed organ failure (organ failure
group; mean age 52 ± 0.7, 75% male, aetiology: alcohol
75%, other 11%, both 14%, Table 1). Thirty-day mortality
of the 159 patients who developed organ failure was 58%.
(Figure 2a, Table 1). Forty-two patients (26%) were not
admitted to ICU.
Factors associated with mortality in the organ failure
group according to PIRO classification
Predisposition (P)
Age, gender and aetiology of liver disease as possible
predisposing factors were not different between survi-
vors and non-survivors. Although more men developed








Age 53.1 ± 0.5 53.6 ± 0.72 52.0 ± 0.7
Gender (M/F) 322/153 203/113 119/40*
Aetiology of cirrhosis 354 (74%) 239 (75%)
Alcohol 92 (19%) 52 (16%) 115 (72%)
Hepatitis B/C 31 (7%) 27 (8%) 40 (24%)
Others 4 (3%)
INR 1.70 ± 0.03 1.67 ± 0.05 1.76 ± 0.04
Bilirubin (umol/l) 156.9 ± 8.5 98.9 ± 7.2 273.5 ± 17.9***
Albumin (g/L) 28.7 ± 0.6 30.0 ± 0.8 25.8 ± 0.5***
Creatinine (umol/L) 110.4 ± 4.0 93.4 ± 1.2 146.8 ± 11.7***
Child-Pugh score 10.7 ± 0.1 10.3 ± 0.4 11.2 ± 0.2***
MELD score 12.3 ± 0.4 10.5 ± 0.1 16.4 ± 0.8***
ALT (U/L) 69.4 ± 8.0
Haemoglobin (g/dL) 10.4 ± 0.8
Platelets (x109/L) 111.5 ± 6.1
Heart rate (/min) 96 ± 1.6
Body temperature (°C) 36.8 ± 0.1
Previous decompensation
Ascites 52 (32)
Variceal bleed 36 (22)
Hepatic encephalopathy 22 (14)
Jaundice 47 (29)
Precipitating event (I)
Infection 171 (54) 76 (47)
Variceal bleed 108 (32) 46 (28)
Alcohol binge 127 (40) 76 (47)
Others 48 (16) 25 (16)
Response (R)
SIRS - 71 (45)
CRP 31.2 ± 5.4 56.4 ± 3.3***
Infection - 50 (31)
Organ failure (O) None (0) All (159)
APACHE II - 13.5 ± 0.6
SOFA - 8.3 ± 0.8
MARS therapy 0 (0) 43 (27)
In-hospital mortality 118/477 (25) 25/318 (8) 93/159 (58)***
Data expressed as mean (SEM). *P < 0.05 compared to non-organ failure group. **P < 0.01 compared to non-organ failure group. ***P < 0.001 compared to non-
organ failure group. ALT, alanine aminotranferase; APACHE II, Acute Physiology, Age and Chronic Health Evaluation; CRP, C-reactive protein; INR, international
normalised ratio; MARS, molecular adsorbent recirculating system; MELD, Model for End-Stage Liver Disease; SIRS, Systemic Inflammatory Response Syndrome;
SOFA, Sepsis Organ Failure Assessment.
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organ failure (37% versus 26%, P = 0.02), there was no
difference in mortality between men and women in the
organ failure (OF) group. For baseline biochemistry and
comparisons between survivors and non-survivors see
Table 2. Non-survivors had significantly higher levels of
creatinine, bilirubin, prothrombin time (PT), interna-
tional normalised ratio (INR), and activated partial
thromboplastin time (aPTT) and lower albumin levels
compared to survivors at baseline. Bilirubin and INR
were also independent predictors of mortality in the
multivariable analysis. Child and MELD score were pre-
dictive for mortality on univariate analysis (Table 3) but
these scores were not included into the multivariable
analysis.
Seventy of the 159 patients had at least one episode of
decompensation requiring hospital admission within the
previous six months. Thirty-day mortality of patients
with previous decompensation was 79% whereas 39% of
patients without previous decompensation within the
previous six months died in the same period of time
(P < 0.001, Figure 2b). We analysed the predictive utility
of Child and MELD in the two groups using AUROC.
Mortality in patients with previous decompensation was
predicted at lower MELD cutoff scores compared with
the group without previous decompensation (MELD 9.2
vs 10.7; Table S1 in Additional file 1).
Mortality of the patients who recovered from organ
failure in the long-term was significantly worse than in
the patients who did not develop organ failure. In
patients with previous decompensation who went on to
develop organ failure most of the patients died within
one year (85.5%). None of the patients were alive beyond
three years (P < 0.001). In patients who did not develop
organ failure, long-term mortality was dictated by the
severity of their underlying liver disease (Figure 2c).
Comparing patients with and without previous decom-
pensation at baseline showed that patients did not differ
significantly in all variables except for a higher aPTT and a
higher baseline SOFA score in the group with previous
decompensation. There was no difference in precipitating
events for decompensation in patients with or without pre-
vious decompensation and there was also no difference in
the development of new complications between these two
groups (Table S2, S3 in Additional file 1). Previous decom-
pensation within the last six months was an independent
predictor of mortality in multivariable analysis with an
Figure 1 Study flow and summary of outcomes.
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adjusted OR of 4.97. Twenty-three percent of survivors, but
59% of non-survivors had a previous decompensation (P <
0.0001).
Injury (I)
The commonest precipitating illness leading to hospital
admission was infection (47%), which was almost equally
split between spontaneous bacterial peritonitis (54%) and
other infection (chest: 19%; UTI: 12%; infected leg ulcer:
11%; others: 4%). Alcohol binge formed the next largest
group amounting to 47% as well. Variceal bleeding
accounted for about 28% of cases. More than one precipi-
tating event could be present. There were no patients
included in the study who did not have a defined precipi-
tating illness. None of these precipitating factors was able
to distinguish between survivors and non-survivors.
Systemic inflammatory response and infection (R)
SIRS occurred independently of infection. SIRS occurred
in 42% of patients with organ failure and tended to be
more frequent in non-survivors (46% vs 25%, P = 0.051).
SIRS was not associated with the trigger infection.
Survival Analysis
Time










1,0 2 decomepnsated cirrhosis with organ failure















1 ACLF with decompensation within previous 6 months
















1 ACLF with decompensation within previous 6 months
2 ACLF with no decompensation within previous six months
3 decompensated cirrhosis without organ failure
log rank p<0.001
Holm-Sidak test for multiple comparisons (1 vs 2, 1 vs 3, 2 vs 3) p<0.05 
A B
C
Figure 2 Survival analyses of included patients. (a) Thirty-day mortality the patients with and without organ failure (log-rank test: P < 0.001).
The analyses started from the day of onset of organ failure. (b) Thirty-day mortality of patients with organ failure divided according to whether
they had a previous hospital admission with decompensated cirrhosis within the previous six months (log-rank test: P < 0.001). (c) Long-term
outcome of patients with acute deterioration of cirrhosis that did not develop organ failure compared with the patients with organ failure. The
organ failure group is further subdivided into those who required hospital admission with an episode of decompensation within the previous six
months and those that did not (log-rank test: P < 0.001).
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Although baseline C-reactive protein (CRP) was margin-
ally higher in the non-survivors, the most important differ-
ence between the patients who survived was in their ability
of the patients to resolve inflammation indicated by their
ability to reduce CRP compared with the group who died
(Figure 3a and 3b). Twenty-four percent of all patients
with organ failure developed a new infection during ICU
stay and the development of a new infection was associated
with an increased mortality (74.1% vs 44.9%, P < 0.001). No
statistically significant interactions were detected between
the presence of SIRS and infection (P = 0.30).
Organ failure
The development of each new organ failure (see definition
in Methods section) was significantly associated with the
risk of mortality (P < 0.001). Non-survivors had a
significantly higher need for mechanical ventilation, renal
support and inotropes. Hyperbilirubinaemia > 340 umol/L
and coagulation failure (INR > 2.5 or platelets < 20,000)
was significantly more often detected in non-survivors.
Renal failure and the need for inotropes as a measurement
for circulatory failure were significantly associated with
mortality on univariate and multivariable analysis. Hepatic
encephalopathy was not predictive for mortality. SOFA
score and APACHE II on the day of first organ failure pre-
dicted risk of death. The AUROC improved for APACHE
II and SOFA (Table S4 in Additional file 1). If the patient
had a SOFA of 8 or more and this was not improved in a
three-day time period their mortality was significantly
higher (72.3% vs 46.9%, P = 0.013). This failure of
improvement over three days had a sensitivity of 75% and






Age 51.1 ± 1.1 52.5 ± 0.9
Gender (M/F) 47/19 72/21
Aetiology alcohol N (%) 45 (68) 70 (75)
PT (sec) 15.9 ± 0.4*** 20.7 ± 0.6
INR 1.54 ± 0.04** 1.91 ± 0.06
aPTT (sec) 49.9 ± 2.0*** 65.5 ± 3.4
Bilirubin (umol/L) 190.6 ± 20.0*** 331.2 ± 25.4
Albumin (g/L) 27.3 ± 0.9** 24.8 ± 0.7
Creatinine (umol/L) 114.8 ± 13.3*** 170.5 ± 16.9
Child 10.1 ± 0.2*** 12.1 ± 0.2
MELD 12.0 ± 1.0*** 19.6 ± 1.1
Hospitalisation within last 6 months N (%) 15 (23) 55 (59)
Injury
Infection N (%) 28 (42) 54 (58)
Variceal bleed N (%) 22 (33) 23 (24)
Alcohol binge N (%) 40 (60) 47 (51)
Dehydration N (%) 6 (9) 15 (16)
Drugs N (%) 2 (3) 1 (1)
Response
SIRS N (%) 25 (38) 46 (49)
Infection N (%) 12 (18)** 38 (41)
Organ failure
Inotrope N (%) 3 (5)*** 44 (47)
Renal failure N (%) 12 (18)*** 53 (57)
Haemofiltration N (%) 7 (11)*** 38 (41)
Mechanical ventilation N (%) 10 (15)*** 45 (48)
Hepatic encephalopathy 39 (59) 52 (56)
Hyperbilirubinemia > 340 umol/l 10 (15)*** 38 (41)
Severe coagulopathy 1 (2)** 15 (18)
APACHEII 10.9 ± 0.8* 15.1 ± 0.8
SOFA 6.7 ± 0.3** 9.4 ± 0.3
*P < 0.05; **P < 0.005; ***P < 0.001; data expressed as mean (SEM). APACHE II, Acute Physiology, Age and Chronic Health Evaluation; aPTT, activated partial
thromboplastin time; INR, international normalised ratio; MELD, Model for End-Stage Liver Disease; PT, prothrombin time; SIRS, Systemic Inflammatory Response
Syndrome; SOFA, Sepsis Organ Failure Assessment.
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a specificity of 48% to predict death. When patients with
SOFA of 8 or more were analysed for improvement of
SOFA over seven days, failure of improvement had a sen-
sitivity of 74% and a specificity of 61% to predict mortality.
Discussion
The results of this study support the hypothesis that the
occurrence of organ failure in patients with acute dete-
rioration of cirrhosis defines a prognostically and patho-
physiologically distinct group. Our data also identify the
occurrence of organ failure rather than the severity of liver
dysfunction as important factor in determining the prog-
nosis of patients. The demonstration of more than twice
the mortality rate in the patients that developed organ fail-
ure and had previous decompensation of liver disease illus-
trates that physiological reserve is important. From a
pathophysiological perspective, the data suggest that an
altered host response to injury is important in determining
the outcome of patients providing the basis of novel prog-
nostic and therapeutic targets.
The outcome of the patients with an episode of decom-
pensated cirrhosis that results in hospital admission is in
Table 3 Univariate and multivariable logistic regression analysis of mortality at the time first organ failure is
diagnosed.
Univariate Multivariable
Risk factor N Crude OR
(95% CI)




Age 159 1.02 (0.98, 1.05) 0.324
Gender (M/F) 159 0.72 (0.35, 1.48) 0.375
Aetiology alcohol 159 1.42 (0.71, 2.86) 0.325
PT (sec) 128 1.44 (1.23, 1.68) < 0.0001
INR (per unit) 159 8.94 (3.12, 25.66) < 0.0001 6.43 (1.82, 22.71) 0.004
aPTT (sec) 132 1.04 (1.01, 1.06) 0.001
Bilirubin (per 10 umol/L) 158 1.03 (1.02, 1.05) < 0.0001 1.04 (1.02, 1.07) 0.001
Albumin (g/L) 145 0.94 (0.89, 0.99) 0.027
Creatinine
(per 10 umol/L)
148 1.04 (1.00, 1.07) 0.028
Child score 152 1.91 (1.51, 2.41) < 0.0001
MELD score 146 1.09 (1.05, 1.14) < 0.0001
Hospitalisation within last 6 months 159 4.92 (2.42, 10.00) < 0.0001 4.97 (1.89, 13.09) 0.001
Injury
Infection 159 1.88 (0.99, 3.56) 0.053
Variceal bleed 159 0.66 (0.33, 1.32) 0.237
Alcohol binge 159 0.66 (0.35, 1.26) 0.210
Dehydration 159 1.92 (0.70, 5.25) 0.202
Drugs 159 0.35 (0.03, 3.92) 0.393
Response
SIRS score 158 1.38 (1.00, 1.91) 0.051
Infection 152 3.05 (1.43, 6.49) 0.004
Organ failure
Inotrope 152 18.81 (5.49, 64.45) < 0.0001 14.70 (3.18, 68.03) 0.001
Renal failure 153 6.09 (2.86, 12.97) < 0.0001 3.46 (1.18, 10.12) 0.023
Haemofiltration 152 5.96 (2.45, 14.53) < 0.0001
Mechanical ventilation 152 5.42 (2.45, 11.98) < 0.0001
Hepatic encephalopathy 159 0.88 (0.46, 1.66) 0.690
Hyperbilirubinemia > 340 umol/l 159 3.87 (1.76, 8.52) 0.001
Severe coagulopathy 144 13.24 (1.70, 103.20) 0.014
APACHE II score 114 1.12 (1.04, 1.20) 0.002
SOFA score 153 1.51 (1.29, 1.77) < 0.0001
Due to different amount of missing data and correlations among predictors, stepwise selection was done manually to build the multivariable model. 151
observations were included in the final multivariable analysis. The scores (Child, MELD, SOFA, APACHE II) were not incorporated into the multivariable analysis.
APACHE II, Acute Physiology, Age and Chronic Health Evaluation; aPTT, activated partial thromboplastin time; CI, confidence interval; INR, international normalised
ratio; MELD, Model for End-Stage Liver Disease; OR, odds ratio; PT, prothrombin time; SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sepsis Organ
Failure Assessment.
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keeping with the existing previous data. In the group that
did not develop organ failure, in-hospital mortality of 8%
related mainly to non-liver deaths and a median survival
of two years is in keeping with that reported in the litera-
ture [13-15]. A survival of 42% in the group that developed
organ failure supports the view that attention to the preci-
pitating event and early non-specific supportive manage-
ment can prevent progression to full-blown multiorgan
failure. When patients are admitted to ICU, short-term
mortality ranges between 46 and 89% [6,16-31]. These
data suggest that the occurrence of a single organ failure
in patients with a defined severity of liver disease indicates
a poor prognosis. Importantly, both bilirubin and PT were
also independent predictors of mortality in keeping with
previous data, suggesting that liver and/or associated end-
organ failure are associated with poor outcome [6,18,
19,21,22,26-29,32-35].
The most important finding of our study was the
demonstration that despite a similar precipitating illness
and comparable liver function, the patients who had a pre-
vious episode of decompensation requiring hospital admis-
sion within the previous six months were more than twice
Figure 3 Changes in C-reactive protein (CRP) (mean (SD)) over the first seven days in the patients that survived compared with the
patients who died. The data show that there was a significant reduction in CRP in the survivors (ANOVA: P < 0.001) whereas the CRP increased
significantly in the non-survivors (ANOVA: P < 0.05).
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as likely to die if they developed organ failure. This obser-
vation is akin to the ‘P’ component of the PIRO concept
(Predisposition, Insult/Infection, Response, Organ failure)
[7] that has been developed for sepsis-related multiorgan
failure. The mechanism underlying the higher mortality
rate in the patients with previous decompensation is not
clear but is unlikely only to reflect differences in the base-
line liver function, since there was no difference in bio-
chemistry and liver function scores between patients with
and without previous decompensation. It may well indi-
cate that these patients are more susceptible to injury (I of
PIRO) or have an exaggerated inflammatory response with
the same precipitating event. Indeed, infection is present
in 30% of hospital admissions of cirrhotic patients and the
risk of nosocomial infection is nearly six times increased.
Mortality of bacteraemia and sepsis in cirrhosis is mark-
edly increased (recently reviewed in [36] and [37]). Infec-
tion is closely linked with the occurrence of renal
dysfunction, sepsis syndrome and mortality [38-40]. How-
ever, in our study, the type of precipitating event had no
influence on mortality. One would expect that infection or
variceal bleeding causes a higher mortality than other pre-
cipitating events. The reason for this might be that some
precipitating events lead to organ failure more often, but
once organ failure has developed, other factors are more
relevant for outcome.
The host response to injury (R) or infection is clinically
represented in the occurrence of SIRS. In our study group,
we observed SIRS in 42% of patients with organ failure,
indicating that pathophysiology of organ failure is similar to
that of the sepsis syndrome in which SIRS is crucial in the
pathogenesis. However, in our study, SIRS occurred inde-
pendent of infection - either as a trigger or new infections
during the course of illness, indicating that the disease itself
might lead to SIRS or that infection is underdiagnosed in
patients with ACLF. The presence of SIRS has been shown
to be predictive for mortality especially in the subgroup of
patients with cirrhosis and renal failure, independent of the
presence of infection [41]. SIRS also occurs in about 15% of
patients with advanced cirrhosis and acute liver failure and
is associated with mortality [42]. In animal models of cir-
rhosis, administration of lipopolysaccharide (LPS) was asso-
ciated with a prolonged unremitting inflammatory
response, renal dysfunction, encephalopathy and death
[43,44]. Although SIRS is present in a significant proportion
of patients with organ failure, it is possible that this number
is still an underestimation of the true number of SIRS in
these patients. The parameter used as SIRS criteria might
all be affected by liver cirrhosis - baseline polymorphonuc-
lear count might be reduced due to hypersplenism, baseline
heart rate can be elevated because of the hyperdynamic cir-
culatory syndrome, baseline hyperventilation may be pre-
sent due to hepatic encephalopathy and elevation of body
temperature may be blunted in cirrhosis [40]. In our study,
we found that inflammation measured CRP at the onset of
organ failure was not able to predict of outcome. However,
the change in CRP levels over time was able to discriminate
between survivors and non-survivors. The poorer outcome
in the patients whose CRP levels failed to improve leads us
to hypothesise inability to resolve inflammation may be
pathophysiologically important in this syndrome. It has
recently been shown that decreased HLA-DR expression
[45] and a further decrease over three days is noted in non-
survivors, whereas survivors showed increased or at least
unchanged HLA-DR levels [46].
Our initial hypothesis was that patients with organ fail-
ure, who recover, would go back to the clinical state they
were in prior to the decompensating event. However, our
data clearly show that the patients who recover from
organ failure and can be discharged from the hospital
have almost universal mortality over the next three years
(Figure 2c) suggesting the natural history of cirrhosis is
truly altered by the occurrence of organ failure. Similar
observations have been made for sepsis [47], where long-
term mortality after surviving the index intensive care
stay is markedly elevated. So far, it is not fully elucidated,
why a survival from an episode of organ failure does not
lead to complete recovery. Typically in other patient
groups than cirrhosis, acute physiological impairment at
admission did not predict long-term mortality, but age -
in contrast to our cohort - was predictive in other
cohorts.
This study has some limitations: Most patients had alco-
hol as a major or contributory factor, therefore, these
results are most relevant to this patient cohort. However,
in most western countries alcohol plays a major role in
the pathogenesis of cirrhosis. Another limitation is the fact
that we used organ failure scores that were validated in
ICU settings also for patients with organ failure on the
normal wards. Since there are no organ failure scores for
this patient cohort, we believe that it is the best option to
use these ICU scores. A third limitation is that we did not
prospectively collect biologic material from the whole
cohort, therefore, development of novel biomarkers is not
possible from this large cohort of patients.
Conclusions
As has already been described, organ failure is the culmi-
nation of several inter-related pathophysiological pro-
cesses, the presence of which has been described as
ACLF. Our data show that although nearly half of the
patients can be salvaged if they are developing organ fail-
ure, mortality rates become unacceptably high once mul-
tiple organ failure becomes established. Our observations
confirm that the present organ failure scoring systems
can be used to quantify the degree of organ dysfunction
but it is possible that at this stage therapeutic options are
limited and the main strategy is to prevent progression to
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multiple organ failure. Clinical and biochemical markers
that are able to determine which patients will progress to
organ failure following a defined precipitant, is an unmet
clinical need. The PIRO system is conceptually useful as
it indicates a distinction between the insult and the
response. Interventions that target inflammation may
impact adversely on the ability to control the infection
and interventions that target infection may not be useful
if pathophysiological process is being driven through
inflammation. The results of this study provide the fra-
mework for a better pathophysiological understanding of
ACLF taking into account predisposition, injury,
response and organ failure which will need to be vali-
dated in large, ideally multicentre clinical studies.
Key messages
• Acute on chronic liver failure is a clinically and
pathophysiologically distinct entity characterised by
the occurrence of hepatic and extra-hepatic organ
failures.
• Progression to organ failure in patients with liver
cirrhosis is associated with more severe underlying
liver disease and inflammation.
• Previous decompensation, occurrence of new infec-
tion, severity of inflammation, lack of its resolution
and severity of organ failure are associated with
higher mortality.
• The occurrence of organ failure alters the natural
history of cirrhosis - nearly all patients die within
three years.
• A classification based on the PIRO concept may
allow categorisation of patients into distinct patho-
physiologic and prognostic groups and allow a mul-
tidimensional definition of ACLF.
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